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Abstract
Aims Increased visit-to-visit glycaemic variability is independently associated with adverse outcomes in Type 2
diabetes. Our aim was to identify the patient characteristics associated with raised visit-to-visit glycaemic variability in
people with Type 2 diabetes.
Methods A case–control study was conducted to establish associations between HbA1c variability and clinical
covariates in 10 130 people with Type 2 diabetes. Variability was calculated by two metrics [SD and coefficient of
variation (CV)] from a minimum of four HbA1c readings obtained over a 4-year period. High and low variability groups
were defined as the top and bottom tertile of the SD or CV, and used in logistic regression analyses including a number of
clinical and biochemical covariates. The analyses were stratified into low mean (< 53 mmol/mol; 7%) and high mean
(≥ 53 mmol/mol; 7%) HbA1c groups.
Results Findings were consistent across both HbA1c groups and variability metrics. Treatment, independent of other
factors, was the most strongly associated covariate for the risk of high HbA1c variability. A six-fold increased risk was
observed in the low HbA1c group, between the most and least intense treatment regimens (P < 0.001). Similar findings
were present in the high HbA1c group with a three-fold increase in risk (P < 0.001). In addition, male gender, younger
age, reduced HDL-cholesterol and increased BMI were all found to be independently associated with raised visit-to-visit
glycaemic variability.
Conclusions Intensive treatment resulting in low mean HbA1c was associated with marked increase in HbA1c variability.
Irrespective of diabetes control, the greatest visit-to-visit variability was observed in young, insulin resistant men.
Diabet. Med. 35, 262–269 (2018)
Introduction
Pivotal studies over the years have demonstrated the bene-
ficial effects of lowering HbA1c on both micro- and
macrovascular complications in Type 2 diabetes [1,2].
However, on-going debate exists as to whether other factors,
such as glycaemic variability, play a contributory role in the
adverse outcomes of diabetes.
Glycaemic variability is the measure of glycaemic fluctu-
ations over a given time. Clinically, it is an umbrella term for
two distinct measurements: intraday variability (short-term)
and visit-to-visit variability (long-term). HbA1c is most often
used as the measure of glycaemia in the latter. Currently, no
‘gold standard’ metric exists to measure HbA1c variability,
however, it is most commonly expressed as either the
standard deviation (SD) or coefficient of variation (CV) of
the glycaemia measures.
Many studies in Type 2 diabetes cohorts have shown
positive associations between raised visit-to-visit variabil-
ity and adverse outcomes, independent of mean HbA1c
level. A recent meta-analysis identified that renal disease,
cardiovascular disease and mortality were all indepen-
dently associated with raised HbA1c variability [3]. This
analysis included 13 studies, the largest of which con-
tained > 4000 participants [4]. Research in the field of
intraday variability has shown that certain patient fea-
tures and clinical factors are associated with raised short-
term glycaemic variability [5–8]. However, we identified
no similar studies in the field of long-term glycaemic
variability.
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The detrimental consequences of high intraday variability
have been mapped at a cellular level and are well docu-
mented [9–12]. The cellular effects of elevated HbA1c
variability are unknown, which gives rise to the possibility
that two distinct biological processes are occurring. Estab-
lishing whether the same patient characteristics are associ-
ated with both raised intraday and HbA1c variability is of
interest because the findings could provide an insight into the
biological processes responsible for increased HbA1c vari-
ability and its associated adverse outcomes.
The aim of our research was to identify the patient
characteristics associated with the risk of raised HbA1c
variability in a large Type 2 diabetes cohort.
Participants and methods
Study setting and design
A case–control study of HbA1c variability was conducted in
Tayside and Fife (Scotland, UK). Data were gathered from
the Scottish Care Information-Diabetes Collaboration (SCI-
DC); the electronic health record system used in Scotland for
people with diabetes. We identified a source population of
13 285 individuals with Type 2 diabetes. Biochemical,
demographic and prescribing data were available for these
participants across a 20-year period since 1994.
Participants with at least four HbA1c recordings within a 4-
year window of time between 1 January 2010 and 1 January
2014 were included in this study (Fig. 1). Baseline data on
covariates were gathered at 1 January 2010 ( 6 months). If a
participant had more than one covariate recording, the mean
of these values was calculated. For those with more than
one treatment therapy recorded, the latest listed was used for
the analysis; this treatment was themost likely to be continued
due to the stepwise progression of diabetes management.
Each participant had their glycaemic variability defined by
two metrics; the SD and the CV, which was 100 9 SD/mean
HbA1c. Two HbA1c variability groups were then constructed
encompassing the top tertile of the distribution (high
variability = cases) and bottom tertile of the distribution
(low variability = controls) respectively (Fig. 2). This process
was carried out for both SD and CV.
Statistical analyses
Analysis of variance (ANOVA) and chi-square tests were
used to compare means and frequencies among subgroups of
participants respectively. Tests of association with HbA1c
variability (coded as binary, high = case vs. low = control)
were performed using unconditional logistic regression
models. Univariate models were used to determine the
patient characteristics associated with glycaemic variability,
and potential determinants (gender, age, duration of
Type 2 diabetes, diabetes treatment, HDL-cholesterol,
BMI, social deprivation and number of HbA1c readings)
were considered in the analysis. We then developed a
multivariate model, including covariates where the uni-
variate P-value for the trait association was ≤ 0.2 [13].
This analysis was carried out for both variability metrics
(i.e. SD and CV). We used the goodness-of-fit approach
described by Hosmer and Lemeshow to test how well the
derived model fitted the data [14]. Two-way interactions
were additionally tested for between participant gender
and the other covariates included in our final multivariate
model.
Preliminary analyses revealed a strong positive association
between mean HbA1c level and high variability. Subse-
quently, the data were stratified into two groups based upon
mean HbA1c level. The HbA1c value of 53 mmol/mol (7.0%)
was selected as the cut-off, creating a low mean HbA1c group
(< 53 mmol/mol; 7.0%) and a high mean HbA1c group
(≥ 53 mmol/mol; 7.0%) which were used in all subsequent
analyses. This HbA1c cut-off of 53 mmol/mol (7.0%) was
chosen for two reasons: first, it split our sample distribution
into two groups with a large number of participants in each;
and second, it is a clinical target for HbA1c treatment in
people with Type 2 diabetes [15].
FIGURE 1 Depiction of the retrospective data collection process.
What’s new?
• Increased visit-to-visit HbA1c variability has previously
been associated with increased risk of adverse out-
comes, including microvascular and macrovascular
disease.
• We determined the patient characteristics associated
with raised visit-to-visit glycaemic variability, indepen-
dent of the mean HbA1c level and established that these
people with highly variable Type 2 diabetes have
increased cardiovascular disease risk factors including
male gender, raised BMI and reduced HDL-cholesterol
compared with those with low variability.
• People with Type 2 diabetes receiving greater intensity
of treatment (e.g. insulin treatment or triple oral
therapy) have greater visit-to-visit variability than those
who are diet or monotherapy treated.
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Sensitivity analyses were performed to determine if
extreme mean HbA1c values were driving the analyses and
whether insulin treatment, in isolation, was associated with
increased variability. The first analysis removed all partici-
pants with a mean HbA1c < 48 mmol/mol (6.5%) and
> 75 mmol/mol (9.0%) from the cohort, after which the
previously described multivariate analysis was carried out.
The second sensitivity analysis was a whole sample multi-
variate analysis in which the three previously used treatment
groups were broken down into five individual categories to
specifically focus on any potential associations between the
use of insulin and variability. The final sensitivity analysis
carried out addressed the issue of therapy changes across the
4-year HbA1c collection window. Participants who had a
different final treatment from their baseline recording were
removed prior to the creation of the model. Statistical
analyses were conducted using STATA/SE version 14 soft-
ware (StataCorp, College Station, TX, USA), and the
statistical significance level set at P < 0.05.
Results
Some 10 130 participants were included in the analysis and
their baseline characteristics are shown in Table 1. A total of
Low Variability
n=2,709
Moderate Variability
n=1,276
High Variability
n=348
Low Variability
n=669
Moderate Variability
n=2,100
High Variability
n=3,028
Low Mean HbA1c Group
<53 mmol/mol (7%)
n=4,333
High Mean HbA1c Group
53 mmol/mol (7%)
n=5,797
10,130 participants
10,232 participants
11,262 participants
11,453 participants
11,632 participants
11,707 participants
12, 379 participants
13,285 participants with a type 2 diabetes 
diagnosis prior to the reference date
906 participants removed due to lack of HDL 
recording within the reference date window 
672 participants removed due to lack of BMI 
recording within the reference date window 
75 participants removed due to lack of treatment 
recording within the reference date window 
179 participants removed due to uncertainty 
regarding treatment therapy
191 participants removed due to missing social 
deprivation data
1,030 participants removed due to having an 
insufficient number of HbA1c readings
102 participants removed due to significantly 
outlying normal distribution of variability
FIGURE 2 Flow chart showing how the participant sub-groups were created when variability was defined as the standard deviation of the HbA1c
readings.
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3378 participants were categorised as having low HbA1c
variability, of whom 2709 had a mean HbA1c < 53 mmol/
mol (7.0%) and 669 had a mean HbA1c ≥ 53 mmol/mol
(7.0%). The high HbA1c variability group contained 3376
participants, of whom 348 had a mean HbA1c < 53 mmol/
mol (7.0%) and 3028 had a mean HbA1c ≥ 53 mmol/mol
(7.0%). The characteristics of the 1030 people with Type 2
diabetes excluded from the analysis due to an insufficient
number of HbA1c readings are shown in Table S1.
Similar results were observed using both the SD and CV as a
measure of HbA1c variability. However, the ‘goodness of fit’
score in the logistic regression models was superior when
using the SD compared to the CV. Therefore, the results of the
analysis are presented purely for the SD.
Univariate logistic regression revealed that a number of
covariates were associated with HbA1c variability in both the
low and high mean HbA1c strata (Table S2). The low mean
HbA1c analysis found that: men had greater odds of having
high HbA1c variability compared with women [ odds ratio
(OR) 1.45, 95% CI 1.16–1.82, P = 0.001]; participants aged
< 55 years were more likely to be highly variable compared
with those aged 75 years and older (OR 3.05, 95% CI 2.12–
4.39, P < 0.001); and both lower HDL-cholesterol and
higher BMI were associated with raised HbA1c variability.
Participants treated with medication had markedly increased
variability compared with those whose diabetes was diet
controlled. The odds of high HbA1c variability were greater
in the ‘triple or insulin’ group compared with the ‘mono or
dual’ therapy group. Finally, a short duration of diabetes was
marginally associated with lower risk of high HbA1c
variability. Similar results were seen in the high mean HbA1c
group, although the previously observed protective effect
regarding duration of Type 2 diabetes was not significant in
this analysis.
The results of the stratified multivariate logistic regression
models are shown in Table 2. The models were adjusted for
social deprivation and the number of HbA1c measures.
These multivariate models are consistent with the univariate
analysis showing that the previous findings are indepen-
dent of other variables. The goodness-of-fit scores for the
low (chi2 = 1736.72, P = 0.82) and high (chi2 = 2219.15,
P = 0.72) mean HbA1c strata models indicated that both
fitted the data well. In addition, none of the two-way
interactions tested between gender and other covariates
were statistically significant. Table 2 shows that those in the
‘triple or insulin’ treatment group were over six times more
likely to be highly variable than those whose diabetes was
diet treated in the low mean HbA1c strata (OR = 6.64, 95%
CI 3.72–11.86, P < 0.001). This large increase in risk was
also observed in the high mean HbA1c group with a greater
than three-fold increase compared with those whose dia-
betes was diet treated (OR 3.15, 95% CI 2.21–4.47,
P < 0.001). In addition to this, younger people with Type 2
diabetes when compared with their older counterparts
remained far more likely to be highly variable. In both
HbA1c strata those < 55 years old were more than twice as
likely to have high HbA1c variability compared to those
aged 75 and older.
Some 6763 participants were included in the first sensitivity
analysis, which removed those with low mean HbA1c
(< 48 mmol/mol; 6.5%) and high mean HbA1c (> 75 mmol/
mol; 9%). The low variability group contained 2255 partic-
ipants, of whom 1110 had a mean HbA1c < 53 mmol/mol
(7.0%) and 1145 had a mean HbA1c ≥ 53 mmol/mol (7.0%).
Table 1 Baseline characteristics
Characteristic All (n = 10 130)
Low variability
controls (n = 3378)
High variability
cases (n = 3376)
P value
(low vs high)
Gender, n (%) < 0.001
Female 4628 (45.7) 1735 (51.4) 1452 (43.0)
Male 5502 (54.3) 1643 (48.6) 1924 (57.0)
Age (years) 66.9 (11.1) 70.1 (10.4) 64.3 (11.4) < 0.001
Type 2 diabetes duration (years) 5.1 (4.0) 4.5 (3.8) 5.6 (4.1) < 0.001
Treatment, n (%) < 0.001
Diet 3386 (33.4) 1805 (53.4) 638 (18.9)
Mono or dual 5456 (54.9) 1456 (43.1%) 2008 (59.5)
Triple or insulin 1288 (12.7) 117 (3.5%) 730 (21.6)
HDL-cholesterol (mmol/L) 1.22 (0.34) 1.32 (0.37) 1.15 (0.31) < 0.001
BMI (kg/m2) 31.7 (6.2) 30.4 (5.9) 33.0 (6.5) < 0.001
Social deprivation (SIMD), n (%) < 0.001
1 (most deprived) 2110 (20.8) 667 (19.8) 764 (22.6)
2 2189 (21.6) 703 (20.8%) 788 (23.3%)
3 2006 (19.8) 627 (18.6%) 682 (20.2%)
4 1923 (19.0) 679 (20.1%) 603 (17.9%)
5 (least deprived) 1902 (18.8) 702 (20.8%) 539 (16.0%)
No. of readings 7.9 (2.6) 7.0 (2.0) 8.7 (2.9) < 0.001
HbA1c (mmol/mol) 57 (12) 48 (7) 66 (12) < 0.001
HbA1c (%) 7.4 (1.1) 6.5 (0.7) 8.2 (1.1) < 0.001
Values are reported as the mean (SD), unless indicated otherwise.
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The high variability group in this analysis contained 2254
participants, of whom 225 had a mean HbA1c < 53 mmol/
mol (7.0%) and 2029 had a mean HbA1c ≥ 53 mmol/mol
(7.0%). This cohort was used in an identical multivariate
model and showed that the same factors were associated with
increased HbA1c variability independent of other variables
when extreme HbA1c values are removed (Table S3). The
goodness-of-fit scores for the low and high mean HbA1c strata
were (chi2 = 1014.87, P = 0.50) and (chi2 = 2058.30,
P = 0.40) respectively.
Creating five individual treatment categories in the second
sensitivity analysis revealed that those treated with insulin
were more likely to be highly variable than those who were
taking triple oral therapy in the low mean HbA1c strata;
however, this was not seen in the high mean HbA1c group
(Table S4). It is important to note that a larger number of
participants were taking triple oral therapy or insulin in the
high mean HbA1c strata (n = 774) compared with the low
mean HbA1c strata (n = 73).
Of the 9804 participants with a documented final drug
therapy, 6165 did not change their treatment therapy from
baseline and were included in the third sensitivity analysis.
The findings from this analysis were in keeping with the
results of the previous multivariate analyses (Table S5).
Further analysis revealed that 11.2% of participants in the
low variability group changed their treatment during the 4
years compared with 58.8% of those in the high variability
group.
Discussion
The findings of our analysis revealed that young, insulin-
resistant men are most at risk of having high HbA1c
variability. In addition, the participant’s prescribed treatment
was found to be the largest independent predictor of risk.
These findings were seen in both the low mean and high
mean HbA1c groups. The choice of variability metric,
whether SD or CV, had little effect on the results of our
analysis.
Comparing our results with the most similar study
identified in the field of short-term variability is of interest.
Murata et al. [8] found in a cohort of 204 veterans with
insulin-treated Type 2 diabetes that high glucose variability
over 8 weeks was associated with older age and a longer
diabetes duration. In addition, obesity and those treated with
larger insulin doses were found to have lower variability. By
contrast, we show the opposite findings for HbA1c variabil-
ity. The difference between the patient characteristics asso-
ciated with short-term and long-term variability implies that
the underlying mechanisms responsible may differ. This
discovery further supports the role of visit-to-visit variability
as a discrete entity of the glycaemic variability research field
and provides a starting point for future work to understand
the biological mechanisms responsible for raised HbA1c
variability.
We show that the people with Type 2 diabetes most likely
to have highly variable HbA1c are those with high BMI and
Table 2 Multivariate whole sample analysis showing the odds of being highly variable
Variable
Low mean HbA1c (n = 3057) High mean HbA1c (n = 3697)
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Gender
Female 1.00 1.00
Male 1.35 (1.05–1.74) 0.018 1.24 (1.03–1.49) 0.023
Age, years
≥ 75 1.00 1.00
≥ 65 to < 75 1.16 (0.86–1.58) 0.328 0.88 (0.70–1.11) 0.287
55 to < 65 1.22 (0.87–1.72) 0.249 1.49 (1.16–1.92) 0.002
< 55 2.29 (1.51–3.49) < 0.001 2.36 (1.72–3.24) < 0.001
Type 2 diabetes duration, years
> 7 1.00 1.00
2.5–7 0.86 (0.63–1.16) 0.322 0.95 (0.76–1.18) 0.618
< 2.5 0.98 (0.70–1.37) 0.904 1.36 (1.04–1.79) 0.026
Treatment
Diet 1.00 1.00
Mono or dual 3.02 (2.30–3.96) <0.001 1.44 (1.14–1.82) 0.002
Triple or insulin 6.64 (3.72– 11.86) <0.001 3.15 (2.21–4.47) < 0.001
HDL-cholesterol, mmol/L
> 1.3 1.00 1.00
1.0–1.3 1.47 (1.11–1.95) 0.007 1.39 (1.13–1.71) 0.002
< 1.0 1.79 (1.29–2.48) < 0.001 1.87 (1.46–2.39) < 0.001
BMI, kg/m2
< 25 1.00 1.00
25–35 1.15 (0.78–1.69) 0.479 1.22 (0.90–1.65) 0.205
> 35 1.62 (1.05–2.52) 0.030 1.72 (1.22–2.43) 0.002
Adjusted for social deprivation and number of readings.
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low HDL-cholesterol. This is of interest given the previously
reported association of HbA1c variability with increased risk
of adverse outcomes including cardiovascular disease [3,4].
Our findings suggest that this association may not be causally
related to HbA1c variability, but might reflect the high
cardiovascular disease risk characteristics of this cohort.
HbA1c variability is likely to be caused by a number of
factors, predominantly related to variability in lifestyle, such
as exercise [16], high stress [17] and poor treatment
adherence [18]. In addition to lifestyle factors, is it also
likely that underlying biological mechanisms play a role in
HbA1c variability. For example, some people with Type 2
diabetes may be better than others at compensating for
increased metabolic demands seen with episodic poor diet or
illness. An extreme example of this can be found with
glucokinase-maturity-onset diabetes of the young. These
people with diabetes have impaired glucose-sensing abilities
which results in mildly elevated blood glucose levels [19].
The HbA1c readings of these individuals remain constant
regardless of lifestyle and treatment interventions [20],
consistent with these individuals being able to compensate
for increased demand by increasing insulin secretion. The
biological mechanisms underlying HbA1c variability in
Type 2 diabetes are not known, and further work is required
in this area.
One potential limitation of our study was the positive
correlation between mean HbA1c level and HbA1c variabil-
ity. We wanted to draw associations based solely on HbA1c
variability, not mean HbA1c level, which has previously
proven associations with both micro- and macrovascular
complications. To minimize this effect, we stratified the
analysis by mean HbA1c level. The results generated were
consistent across both mean HbA1c groups, strongly
suggesting that the patient characteristics identified were
associated with raised HbA1c variability and not mean
HbA1c level. We also undertook a sensitivity analysis
removing those with mean HbA1c > 75 mmol/mol (9%)
and < 48 mmol/mol (6.5%), and showed similar results to
our full model. Another potential limitation to our model
was underlying diabetes progression as those progressing
rapidly will have a higher SD. To minimize the impact of
progression we chose a 4-year window for HbA1c readings to
accurately assess long-term variability, while limiting the risk
of falsely identifying fast progressors as having high HbA1c
variability. Finally, we acknowledge that this is an observa-
tional study, and although we have adjusted for potential
measured confounders (such as social deprivation and
number of HbA1c measures) our results could still be affected
by unmeasured confounders.
To determine HbA1c variability, multiple HbA1c readings
are required. In this study, 1030 participants were excluded
due to an insufficient number of HbA1c measures, leaving a
select group of people with Type 2 diabetes who have four or
more HbA1c readings over 4 years for further analysis. There
are several potential clinical reasons why a person with
Type 2 diabetes may need to be monitored more closely than
another which must be considered when interpreting our
results. In this study, the number of readings was adjusted for
in all our multivariate models and the baseline characteristics
of this excluded cohort were similar to those of the
participants included in our final analysis (Table S1).
Some 3639 participants changed their treatment over the
4-year window used to define HbA1c variability, with
treatment change being more common in the high variability
group than the low variability group. This difference might
reflect that those who are more variable are consequently
more likely to receive additional treatment (as for a given
mean HbA1c, their HbA1c readings are more likely to go high
than those with low variability and this may precipitate new
treatment). An alternative explanation is that starting a new
drug results in a large change in HbA1c that makes the HbA1c
recorded during these 4 years more variable (i.e. the HbA1c
variability is not a measure of intrinsic variability but is
secondary to treatment change). To ensure that this latter
scenario was not driving our results, a sensitivity analysis
was carried out which showed almost identical results to our
main analysis.
The treatment prescribed to a person with Type 2 diabetes
was found to be strongly associated with their risk of having
highly variable HbA1c. This is particularly striking in the
stratum with mean HbA1c < 53 mmol/mol (7%). In this
group, the participants who were intensively treated, with
triple oral therapy or insulin, to achieve this target had a
more than six-fold increased risk of having highly variable
HbA1c. Within this group, greater variability again was seen
in those on insulin compared with triple oral therapy,
although the numbers were small. A similar pattern is seen in
the stratum with HbA1c ≥ 53 mmol/mol (7%), although the
effect is less strong and there is no greater risk of insulin
treatment over triple oral therapy. These results are of
interest, especially in the context of the outcomes of the
ACCORD study where aggressive treatment initiated to
achieve a treatment target of 48m mol/mol (6.5%) resulted
in increased mortality compared with a less aggressive target
[21]. Our findings show that people with Type 2 diabetes
who are treated intensively to reach a mean HbA1c
< 53 mmol/mol (7%) have much more variability between
visits in their HbA1c than those who are likely closer to
diagnosis requiring no treatment or monotherapy. At this
level, 11.5% of the participants with highly variable HbA1c
on triple oral therapy or insulin had at least one HbA1c
reading < 37 mmol/mol (5.5%); whereas 46.2% of the same
cohort had a reading > 69 mmol/mol (8.5%). If HbA1c
variability per se is associated with increased risk of
cardiovascular disease, this may explain the adverse out-
comes found in ACCORD. Our findings support the
rationale in the guidelines that emerged after ACCORD,
that there should be a low HbA1c target in those early in the
disease process and a less aggressive target once treatment
has intensified [15,22]. It should be noted, however, that our
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analysis cannot ascribe a causal association between inten-
sive treatment regimens and high HbA1c variability. Individ-
uals with high HbA1c variability will have large fluctuations
in HbA1c that are likely to result in treatment intensification;
conversely more intense treatment, especially with insulin,
may result in more variability in glycaemic control.
In conclusion, we report, for the first time, the patient
characteristics associated with high and low visit-to-visit
variability in HbA1c. We have shown that intensive treatment
is associated with high HbA1c variability, especially in those
with a mean HbA1c < 53 mmol/mol (7%). We also demon-
strate that those with high HbA1c variability are more likely
to be male, younger and with low HDL-cholesterol. Further
work is required to investigate how HbA1c variability varies
over the life course of someone’s diabetes and with different
diabetes treatments; and more complex models are required
to account for underling disease progression. Our findings
suggest that those who are more likely to have high HbA1c
variability are those who have more cardiovascular risk
factors. Given this, it is uncertain whether the adverse
cardiovascular disease outcomes reported to be associated
with increased HbA1c variability can be attributed to the high
HbA1c variability per se, or more simply reflects the high
cardiovascular risk factors seen in people with Type 2
diabetes who exhibit high HbA1c variability. One potential
way to unravel this causality question would be to use
Mendelian randomization if suitable genetic instruments can
be found.
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online version of this article:
Table S1. Baseline characteristics of included and excluded
participants.
Table S2. Univariate whole sample analysis showing the
odds of high HbA1c variability.
Table S3. Sensitivity analysis 1: multivariate analysis show-
ing the odds of high HbA1c variability with extreme mean
HbA1c values removed.
Table S4. Sensitivity analysis 2: multivariate whole sample
analysis showing the odds of high HbA1c variability with
further differentiation of treatment groups.
Table S5. Sensitivity analysis 3: multivariate analysis show-
ing the odds of high HbA1c variability with participants that
changed treatment therapy removed.
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